The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 23.13 — safe zoneOK
- Earnings-manipulation signal · Beneish M 18.59 — flag raised, worth a closer lookWatch
- Earnings quality 63/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as CG Oncology, Inc. reports it. History and quarterly detail are in the app.
- Commercial And Development Revenue$3.2M
- License And Collaboration Revenue$806K
Leadership changes
From CG Oncology, Inc.'s own filings, the day they're filed.
- Jim DeTore · Chief Financial Officer · appointmenteff. 2026-04-13
- Jim DeTore · appointmenteff. 2025-11-30
- Robert Lapetina · interim principal financial and accounting officer of CG Oncology · departureeff. 2025-11-30
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-05-26
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CG Oncology, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when CG Oncology, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.